Dynavax Technologies in partnership with GlaxoSmithKline have consequently developed DV1179, a bifunctional inhibitor of TLR7 and TLR9, which has been shown to reverse glucocorticoid resistance in both human cells and animal models of lupus. The gene discussed is TLR7; the disease is systemic lupus erythematosus.